Get the Stockscreener App
73.24
4.85%
3.39
After Hours:
73.24
Vaxcyte Inc stock is traded at $73.24, with a volume of 1.32M.
It is up +4.85% in the last 24 hours and down -14.26% over the past month.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.
See More
Previous Close:
$69.85
Open:
$70
24h Volume:
1.32M
Relative Volume:
1.22
Market Cap:
$9.43B
Revenue:
-
Net Income/Loss:
$-507.65M
P/E Ratio:
-15.92
EPS:
-4.6
Net Cash Flow:
$-616.24M
1W Performance:
-0.88%
1M Performance:
-14.26%
6M Performance:
-35.83%
1Y Performance:
+2.26%
1-Day Range:
$70.00
$75.00
1-Week Range:
$67.23
$76.38
52-Week Range:
$58.10
$121.06
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
73.24 | 9.43B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
Learn to Evaluate (PCVX) using the Charts - Stock Traders Daily
Vaxcyte’s SVP Mikhail Eydelman sells shares worth $353,699 By Investing.com - Investing.com Australia
Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares - GuruFocus.com
Mutual of America Capital Management LLC Lowers Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Bank of New York Mellon Corp Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Vaxcyte’s SVP Mikhail Eydelman sells shares worth $353,699 - Investing.com
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Truist Financial Corp - Defense World
Vaxcyte COO Jim Wassil sells $586,165 in stock By Investing.com - Investing.com Australia
Vaxcyte COO Jim Wassil sells $586,165 in stock - Investing.com India
Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Vaxcyte phase II PCV valve to open shortly, Pfizer sizers alert - BioWorld Online
Mizuho maintains Vaxcyte stock Outperform rating, $163 target - Investing.com India
Sanctuary Advisors LLC Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
(PCVX) Trading Report - Stock Traders Daily
Research Analysts Offer Predictions for Vaxcyte Q1 Earnings - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Handelsbanken Fonder AB - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by New York State Common Retirement Fund - Defense World
Vaxcyte’s (PCVX) Buy Rating Reiterated at Needham & Company LLC - Defense World
Q1 Earnings Estimate for Vaxcyte Issued By Leerink Partnrs - Defense World
Guggenheim Reiterates "Buy" Rating for Vaxcyte (NASDAQ:PCVX) - MarketBeat
Vaxcyte (NASDAQ:PCVX) Releases Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Vaxcyte's (PCVX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
Vaxcyte’s Promising Prospects and Strategic Engagements Justify Buy Rating - TipRanks
Vaxcyte’s Earnings Call Highlights Strong Position and Future Growth - TipRanks
Vaxcyte cites manufacturing investments at Lonza facility in Visp as key 2024 expenditure - BioProcess Insider
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight - GuruFocus.com
Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy According to Hedge Funds - Insider Monkey
Buy Rating for Vaxcyte Driven by Anticipated Positive Phase 2 Data and Undervalued Stock Potential - TipRanks
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2024 Earnings Call Transcript - Insider Monkey
Vaxcyte Inc (PCVX) Q4 2024 Earnings Call Highlights: Strong Fina - GuruFocus.com
Vaxcyte Advances Vaccine Pipeline with Strong Financial Backing - TipRanks
Vaxcyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Vaxcyte Q4 2024 sees stock dip after earnings - Investing.com
10 Best Vaccine Stocks to Buy According to Hedge Funds - Insider Monkey
Vaxcyte 2024 Loss Narrows -February 25, 2025 at 05:22 pm EST - Marketscreener.com
Vaxcyte, Inc. SEC 10-K Report - TradingView
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Vaxcyte, Inc. (PCVX): Among the Stocks That Will Go to The Moon According to Analysts - Insider Monkey
What's Driving the Market Sentiment Around Vaxcyte? - Benzinga
Vaxcyte’s Promising Growth in the PCV Market: Analyst Recommends Buy Rating - TipRanks
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
BTIG maintains Vaxcyte stock Buy rating, $160 target By Investing.com - Investing.com Canada
Vaxcyte’s Promising Vaccine Developments and Strong Buy Rating Backed by Robust Clinical Trials and DCF Valuation - TipRanks
Rhumbline Advisers Buys 7,711 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Vaxcyte (PCVX) Expected to Announce Earnings on Tuesday - Defense World
Vaxcyte (PCVX) to Release Earnings on Tuesday - Armenian Reporter
Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares - MarketBeat
TimesSquare Capital Management LLC Has $33.86 Million Position in Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):